2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
No.78
“Norursodeoxycholic acid (norUDCA) significantly ameliorates liver injury in the STAM mouse model for non-alcoholic steatohepatitis (NASH)” Dr. Falk Pharma GmbH
No.77
“EC-18, a novel immune resolution accelerator, improves NASH and liver fibrosis Institution” Enzychem Lifesciences Corporation
No.76
“In vitro and in vivo characterization of EYP001 a novel, potent and selective FXR agonist now in a phase 2 clinical trial in NASH Institution” Enyo Pharma SA
No.75
“Change of Gut Microbiome after Treatment with the Traditional Japanese Medicine Daisaikoto is Associated with Improved Liver Steatosis in a Non-alcoholic Fatty Liver Mouse Model” TSUMURA & Co.
No.74
“Influence of the O-GlcNAc Modification in Hepatic Carcinogenesis by Non-alcoholic Fatty Liver Disease” Osaka Medical College